A Novel Cellular Model of Pediatric and Adult BRAFV600E-mutated Papillary Thyroid Cancer

被引：0
|
作者：
O'Neill, Alison [1 ]
Medrano, Victoria Casado [1 ]
Branigan, Grace Purvis [1 ]
Salwen, Madeleine [1 ]
Bauer, Andrew [1 ]
Franco, Aime [1 ]
机构：
[1] Childrens Hosp Philadelphia, 3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA
来源：
HORMONE RESEARCH IN PAEDIATRICS | 2022年 / 95卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
6081
引用
下载
收藏
页码：241 / 242
页数：2
相关论文
共 50 条
  • [1] Obesity Is Associated with BRAFV600E-Mutated Thyroid Cancer
    Rahman, Sabbir T.
    Pandeya, Nirmala
    Neale, Rachel E.
    McLeod, Donald S. A.
    Bain, Chris J.
    Baade, Peter D.
    Youl, Philippa H.
    Allison, Roger
    Leonard, Susan
    Jordan, Susan J.
    THYROID, 2020, 30 (10) : 1518 - 1527
  • [2] Dabrafenib and trametinib in patients with metastatic BRAFV600E-mutated thyroid cancer
    Jeon, Y-K.
    Jung, H. A.
    Park, S.
    Lee, S-H.
    Kim, T. H.
    Kim, S. W.
    Chung, J. H.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1299 - S1299
  • [3] Sustained Response to Vemurafenib in a BRAFV600E-Mutated Anaplastic Thyroid Carcinoma Patient
    Prager, Gerald W.
    Koperek, Oskar
    Mayerhoefer, Marius E.
    Muellauer, Leonhard
    Wrba, Fritz
    Niederle, Bruno
    Zielinski, Christoph C.
    Raderer, Markus
    THYROID, 2016, 26 (10) : 1515 - 1516
  • [4] Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors
    Cabanillas, Maria E.
    Dadu, Ramona
    Iyer, Pryianka
    Wanland, Kacey B.
    Busaidy, Naifa L.
    Ying, Anita
    Gule-Monroe, Maria
    Wang, Jennifer R.
    Zafereo, Mark
    Hofmann, Marie-Claude
    THYROID, 2020, 30 (09) : 1288 - 1296
  • [5] Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma
    Hamidi, Sarah
    Iyer, Priyanka C.
    Dadu, Ramona
    Gule-Monroe, Maria K.
    Maniakas, Anastasios
    Zafereo, Mark E.
    Wang, Jennifer R.
    Busaidy, Naifa L.
    Cabanillas, Maria E.
    THYROID, 2024, 34 (03) : 336 - 346
  • [6] Morphological features that can predict BRAFV600E-mutated carcinoma in paediatric thyroid cytology
    Rossi, E. D.
    Bizzarro, T.
    Martini, M.
    Capodimonti, S.
    Cenci, T.
    Fadda, G.
    Schmitt, F.
    Larocca, L. M.
    CYTOPATHOLOGY, 2017, 28 (01) : 55 - 64
  • [7] Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib
    Car, Iris
    Dittmann, Antje
    Klobucar, Marko
    Grbcic, Petra
    Pavelic, Sandra Kraljevic
    Sedic, Mirela
    BIOLOGY-BASEL, 2023, 12 (04):
  • [8] Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer
    Subbiah, Vivek
    Lassen, Ulrik
    Gasal, Eduard
    Burgess, Paul
    Wainberg, Zev A.
    LANCET ONCOLOGY, 2020, 21 (11): : E516 - E516
  • [9] Single-agent dabrafenib for BRAFV600E-mutated histiocytosis
    Bhatia, Ankush
    Ulaner, Gary
    Rampal, Raajit
    Hyman, David M.
    Abdel-Wahab, Omar
    Durham, Benjamin H.
    Dogan, Ahmet
    Ozkaya, Neval
    Lacouture, Mario E.
    Hajdenberg, Julio
    Ganzel, Chezi
    Diamond, Eli L.
    HAEMATOLOGICA, 2018, 103 (04) : E177 - E180
  • [10] BRAF inhibitors in BRAFV600E-mutated pediatric high-grade gliomas: Upfront or at recurrence?
    Nobre, Liana
    Bouffet, Eric
    NEURO-ONCOLOGY, 2022, 24 (11) : 1976 - 1977
12345